Canada Pension Plan Investment Board Trims Stake in Agilent Technologies, Inc. (NYSE:A)

Canada Pension Plan Investment Board cut its stake in Agilent Technologies, Inc. (NYSE:AFree Report) by 48.5% in the third quarter, Holdings Channel reports. The institutional investor owned 139,460 shares of the medical research company’s stock after selling 131,426 shares during the period. Canada Pension Plan Investment Board’s holdings in Agilent Technologies were worth $15,594,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. increased its position in Agilent Technologies by 1.1% during the 2nd quarter. BlackRock Inc. now owns 31,853,176 shares of the medical research company’s stock valued at $3,830,344,000 after purchasing an additional 349,651 shares during the period. Vanguard Group Inc. increased its position in shares of Agilent Technologies by 1.1% in the first quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock valued at $3,246,209,000 after buying an additional 261,435 shares in the last quarter. State Street Corp increased its stake in shares of Agilent Technologies by 2.0% during the second quarter. State Street Corp now owns 13,214,595 shares of the medical research company’s stock worth $1,591,990,000 after purchasing an additional 253,729 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Agilent Technologies by 0.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 11,076,270 shares of the medical research company’s stock worth $1,238,549,000 after acquiring an additional 39,030 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Agilent Technologies by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 6,378,218 shares of the medical research company’s stock valued at $765,009,000 after acquiring an additional 174,439 shares in the last quarter.

Agilent Technologies Stock Down 0.5 %

NYSE A opened at $133.34 on Monday. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $155.75. The company has a quick ratio of 1.97, a current ratio of 2.61 and a debt-to-equity ratio of 0.47. The business has a 50 day moving average price of $133.27 and a two-hundred day moving average price of $122.01. The stock has a market cap of $39.07 billion, a PE ratio of 31.67, a P/E/G ratio of 3.04 and a beta of 1.11.

Agilent Technologies (NYSE:AGet Free Report) last posted its earnings results on Monday, November 20th. The medical research company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 18.15% and a return on equity of 28.24%. Agilent Technologies’s quarterly revenue was down 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.53 EPS. As a group, sell-side analysts predict that Agilent Technologies, Inc. will post 5.48 EPS for the current fiscal year.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd were issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend was Friday, December 29th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.23. Agilent Technologies’s payout ratio is presently 22.33%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 2,751 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $130.00, for a total transaction of $357,630.00. Following the sale, the chief executive officer now directly owns 306,206 shares of the company’s stock, valued at approximately $39,806,780. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Agilent Technologies news, CEO Michael R. Mcmullen sold 62,467 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $130.00, for a total value of $8,120,710.00. Following the completion of the sale, the chief executive officer now directly owns 306,206 shares of the company’s stock, valued at $39,806,780. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael R. Mcmullen sold 2,751 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $130.00, for a total transaction of $357,630.00. Following the completion of the sale, the chief executive officer now owns 306,206 shares of the company’s stock, valued at $39,806,780. The disclosure for this sale can be found here. Insiders sold a total of 95,929 shares of company stock worth $12,730,599 over the last ninety days.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. UBS Group cut shares of Agilent Technologies from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $163.00 to $125.00 in a research report on Friday, November 17th. Barclays boosted their target price on Agilent Technologies from $100.00 to $120.00 and gave the stock an “underweight” rating in a research note on Thursday, January 25th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 19th. Robert W. Baird lowered their target price on shares of Agilent Technologies from $140.00 to $130.00 and set an “outperform” rating for the company in a research note on Tuesday, November 21st. Finally, TheStreet upgraded shares of Agilent Technologies from a “c+” rating to a “b-” rating in a research note on Friday, December 8th. One research analyst has rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $137.44.

Check Out Our Latest Report on Agilent Technologies

About Agilent Technologies

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Further Reading

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:AFree Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.